Brexafemme

Chemical Nameibrexafungerp
Dosage FormTablet (oral; 150 mg)
Drug ClassTriterpenoid antifungals
SystemMultiple
CompanySCYNEXIS
Approval Year2021

Indication

  • For the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC).
Document TitleYearSource
Brexafemme (ibrexafungerp tablets) Prescribing Information.2022SCYNEXIS Inc., Jersey City, NJ
Drug updated on 12/7/2022

More on this drug: Clinical Trials